Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 726355

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

Isenberg, D; Gordon, C; Licu, D; Copt, S; Rossi, CP; Wofsy, D; Martinović Kaliterna, Dušanka; Morović-Vergles, Jadranka
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) // Annals of rheumatic diseases, 74 (2015), 11; 2006-2015 (podatak o recenziji nije dostupan, članak, znanstveni)

CROSBI ID: 726355 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

Autori
Isenberg, D ; Gordon, C ; Licu, D ; Copt, S ; Rossi, CP ; Wofsy, D ; Martinović Kaliterna, Dušanka ; Morović-Vergles, Jadranka

Izvornik
Annals of rheumatic diseases (0003-4967) 74 (2015), 11; 2006-2015

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Autoantibodies ; Autoimmunity ; B cells ; Infections ; Systemic Lupus Erythematosus

Sažetak
Objectives: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. Methods: In this double-blind, placebo-controlled study, patients with moderate-to-severe SLE were randomised to atacicept 75 mg or atacicept 150 mg administered subcutaneously, or placebo twice-weekly for 4 weeks, then weekly for 48 weeks. Primary and secondary efficacy measures were the proportion of patients experiencing at least one flare of British Isles Lupus Assessment Group A or B, and time to first flare, respectively.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Projekti:
MZOS-198-1081874-0183 - Patogeneza sustavnih poremećaja u reumatoidnom artritisu (Morović-Vergles, Jadranka, MZOS ) ( CroRIS)
NCT00624338

Ustanove:
Klinička bolnica "Dubrava"

Profili:

Avatar Url Jadranka Morović-Vergles (autor)

Avatar Url Dušanka Martinović Kaliterna (autor)

pubmed.ncbi.nlm.nih.gov

Citiraj ovu publikaciju:

Isenberg, D; Gordon, C; Licu, D; Copt, S; Rossi, CP; Wofsy, D; Martinović Kaliterna, Dušanka; Morović-Vergles, Jadranka
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) // Annals of rheumatic diseases, 74 (2015), 11; 2006-2015 (podatak o recenziji nije dostupan, članak, znanstveni)
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C., Wofsy, D., Martinović Kaliterna, D. & Morović-Vergles, J. (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Annals of rheumatic diseases, 74 (11), 2006-2015.
@article{article, author = {Isenberg, D and Gordon, C and Licu, D and Copt, S and Rossi, CP and Wofsy, D and Martinovi\'{c} Kaliterna, Du\v{s}anka and Morovi\'{c}-Vergles, Jadranka}, year = {2015}, pages = {2006-2015}, keywords = {Autoantibodies, Autoimmunity, B cells, Infections, Systemic Lupus Erythematosus}, journal = {Annals of rheumatic diseases}, volume = {74}, number = {11}, issn = {0003-4967}, title = {Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)}, keyword = {Autoantibodies, Autoimmunity, B cells, Infections, Systemic Lupus Erythematosus} }
@article{article, author = {Isenberg, D and Gordon, C and Licu, D and Copt, S and Rossi, CP and Wofsy, D and Martinovi\'{c} Kaliterna, Du\v{s}anka and Morovi\'{c}-Vergles, Jadranka}, year = {2015}, pages = {2006-2015}, keywords = {Autoantibodies, Autoimmunity, B cells, Infections, Systemic Lupus Erythematosus}, journal = {Annals of rheumatic diseases}, volume = {74}, number = {11}, issn = {0003-4967}, title = {Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)}, keyword = {Autoantibodies, Autoimmunity, B cells, Infections, Systemic Lupus Erythematosus} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Podijeli:





Contrast
Increase Font
Decrease Font
Dyslexic Font
CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.